1. Unexplained Abuses of Human IgG Subclass Denomination in Antibody Patents

   • Jérémy Pottier
   • Hervé Watier

   Commentary 23 April 2014 Pages: 327 - 329

2. Multi-Specific Antibodies for Cancer Immunotherapy

   • Ron D. Jachimowicz
   • Sven Borchmann
   • Achim Rothe

   Leading Article 18 March 2014 Pages: 331 - 343

   

3. siRNA Technology in Kidney Transplantation: Current Status and Future Potential

   • Kristina Glebova
   • Oleg N. Reznik
   • Mikhail Skoblov

   Review Article 27 February 2014 Pages: 345 - 361

   

4. Drift, Evolution, and Divergence in Biologics and Biosimilars Manufacturing

   • Sundar Ramanan
   • Gustavo Grampp

   Review Article 25 February 2014 Pages: 363 - 372

   

5. Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook

   • Daniel C. Cho

   Review Article 25 February 2014 Pages: 373 - 381

   

6. Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody–Drug Conjugates

   • Melody Sauerborn
   • William van Dongen

   Review Article 20 May 2014 Pages: 383 - 391

   

7. Purification, Characterization and Plasma Half-Life of PEGylated Soluble Recombinant Non-HA-Binding CD44

   • Anne Pink
   • Aili Kallastu
   • Andres Valkna

   Original Research Article 25 February 2014 Pages: 393 - 402

   

8. Ranibizumab: A Review of its Use in Myopic Choroidal Neovascularization

   • Emma D. Deeks

   Adis Drug Evaluation 28 June 2014 Pages: 403 - 410

   

9. Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders

   • Mark Sanford

   Adis Drug Evaluation 13 June 2014 Pages: 411 - 420